Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Doravirine

FDA-approved product (tablet, oral), marketed as Pifeltro.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Doravirine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Non-nucleoside reverse transcriptase inhibitors
FDA pharmacologic class
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AG06

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Doravirine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Doravirine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Sleep Outcomes and Multidimensional Assessment With Antiretroviral Therapy in People Living With HIV on Dolutegravir- vs Doravirine-Based Regimens

    NCT07673965 · start 2026-08-20

    Registered record
    Registry ID
    NCT07673965
    Conditions
    HIV (Human Immunodeficiency Virus); Sleep
    Interventions
    Tenofovir disoproxil fumarate 300mg / Lamivudine 300mg / Doravirine 100mg; Tenofovir disoproxil fumarate 300mg / Lamivudine 300mg / Dolutegravir 50mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-08-20
    Completion
    2027-11-30
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV (Human Immunodeficiency Virus); Sleep
    InterventionTenofovir disoproxil fumarate 300mg / Lamivudine 300mg / Doravirine 100mg; Tenofovir disoproxil fumarate 300mg / Lamivudine 300mg / Dolutegravir 50mg
    PhasePhase 4
    Registry statusNot yet recruiting

  • A Study of Doravirine/Islatravir in Healthy Lactating Females (MK-8591A-061)

    NCT07086079 · start 2025-09-26

    Registered record
    Registry ID
    NCT07086079
    Conditions
    Healthy
    Interventions
    DOR/ISL
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2025-09-26
    Completion
    2026-02-04
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionDOR/ISL
    PhasePhase 1
    Registry statusCompleted

  • DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or Obesity

    NCT07075146 · start 2025-05-05

    Registered record
    Registry ID
    NCT07075146
    Conditions
    HIV - Human Immunodeficiency Virus; Obesity; Overweight and/or Obesity
    Interventions
    DOR/3TC/TDF; BIC/FTC/TAF
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-05-05
    Completion
    2028-08-01
    Enrolment
    306

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV - Human Immunodeficiency Virus; Obesity; Overweight and/or Obesity
    InterventionDOR/3TC/TDF; BIC/FTC/TAF
    PhasePhase 3
    Registry statusRecruiting

  • Doravirine/Lamivudine (DOR/3TC) as a Maintenance ART in Comparison With Dolutegravir/Lamivudine (DTG/3TC) in PLWH Successfully

    NCT06774872 · start 2025-04-30

    Registered record
    Registry ID
    NCT06774872
    Conditions
    HIV-1-infection
    Interventions
    Doravirine 100Mg Tab and Lamivudine 300 Mg Tab; Dolutegravir 50mg Tab and Lamivudine 300 Mg Tab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-04-30
    Completion
    2028-06-15
    Enrolment
    408

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection
    InterventionDoravirine 100Mg Tab and Lamivudine 300 Mg Tab; Dolutegravir 50mg Tab and Lamivudine 300 Mg Tab
    PhasePhase 2
    Registry statusRecruiting

  • Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses

    NCT06338826 · start 2025-02-01

    Registered record
    Registry ID
    NCT06338826
    Conditions
    HIV Infections; HBV Coinfection
    Interventions
    TDF - 245mg or TAF -25mg associated to 3TC - 300mg or FTC - 200mg and a NNRTI or PI/r or INSTI; Dual therapy with 3TC in combination with DTG or ritonavir-boosted Darunavir (rDVR)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-02-01
    Completion
    2027-09-30
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; HBV Coinfection
    InterventionTDF - 245mg or TAF -25mg associated to 3TC - 300mg or FTC - 200mg and a NNRTI or PI/r or INSTI; Dual therapy with 3TC in combination with DTG or ritonavir-boosted Darunavir (rDVR)
    PhasePhase 2
    Registry statusNot yet recruiting

  • A Study of Doravirine and Islatravir as a Single Entity or Combination Therapy and the Effect of Food in Healthy Adult Participants (MK-8591A-055)

    NCT06719570 · start 2024-01-23

    Registered record
    Registry ID
    NCT06719570
    Conditions
    Healthy
    Interventions
    MK-8591A; Islatravir; Doravine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2024-01-23
    Completion
    2024-03-15
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionMK-8591A; Islatravir; Doravine
    PhasePhase 1
    Registry statusCompleted

  • The Effect on Lipid Profile of Switching to Delstrigo in HIV Positive Patients

    NCT05289986 · start 2023-11-21

    Registered record
    Registry ID
    NCT05289986
    Conditions
    Hiv
    Interventions
    DELSTRIGO 100Mg-300Mg-300Mg Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2023-11-21
    Completion
    2024-11-21
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHiv
    InterventionDELSTRIGO 100Mg-300Mg-300Mg Tablet
    PhasePhase 4
    Registry statusTerminated

  • B-free Multistage Trial

    NCT06037564 · start 2023-11-13

    Registered record
    Registry ID
    NCT06037564
    Conditions
    HIV; Drug Resistance; Drug Drug Interaction
    Interventions
    DOR/DTG/3TC
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Enrolling by invitation
    Start
    2023-11-13
    Completion
    2027-09
    Enrolment
    210

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; Drug Resistance; Drug Drug Interaction
    InterventionDOR/DTG/3TC
    PhasePhase 4
    Registry statusEnrolling by invitation

  • A Randomised, Phase 3 Non-inferiority Study of DOR/3TC/TDF Compared to DTG/TAF/FTC in Participants Infected With HIV-1 Starting First-line Antiretroviral Therapy

    NCT05924438 · start 2023-11-08

    Registered record
    Registry ID
    NCT05924438
    Conditions
    HIV-1-infection
    Interventions
    Delstrigo; KOCITAF
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2023-11-08
    Completion
    2026-06-30
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection
    InterventionDelstrigo; KOCITAF
    PhasePhase 3
    Registry statusActive not recruiting

  • DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)

    NCT05705349 · start 2023-03-08

    Registered record
    Registry ID
    NCT05705349
    Conditions
    HIV-1 Infection
    Interventions
    DOR/ISL; BIC/FTC/TAF; Placebo to DOR/ISL; Placebo to BIC/FTC/TAF
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2023-03-08
    Completion
    2029-08-05
    Enrolment
    537

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionDOR/ISL; BIC/FTC/TAF; Placebo to DOR/ISL; Placebo to BIC/FTC/TAF
    PhasePhase 3
    Registry statusActive not recruiting

  • Study on PhArmacokinetics of First liNe Antiretrovirals in Healthy Breastfeeding Volunteers

    NCT05648201 · start 2023-03-01

    Registered record
    Registry ID
    NCT05648201
    Conditions
    Hiv
    Interventions
    Doravirine 100Mg Tab; Biktarvy 50/200/25 Tab
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2023-03-01
    Completion
    2025-04-28
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHiv
    InterventionDoravirine 100Mg Tab; Biktarvy 50/200/25 Tab
    PhasePhase 4
    Registry statusCompleted

  • Switch Strategy From Etravirine (ETR) to Doravirine (DOR) in Virologically-Suppressed HIV-1 Infected Adults With ETR-Resistance

    NCT05506605 · start 2022-12-12

    Registered record
    Registry ID
    NCT05506605
    Conditions
    HIV-1-infection
    Interventions
    Doravirine 100Mg Tab
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2022-12-12
    Completion
    2024-12
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection
    InterventionDoravirine 100Mg Tab
    PhasePhase 4
    Registry statusUnknown

  • A Cohort Study of Use of Doravirine (DOR) Based Regimens in Clinical Practice in Europe DoRavirine Europe Real World/

    NCT05421806 · start 2022-10-10

    Registered record
    Registry ID
    NCT05421806
    Conditions
    HIV I Infection
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2022-10-10
    Completion
    2026-05
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV I Infection
    InterventionNot recorded
    PhaseNot recorded
    Registry statusActive not recruiting

  • Adipose Tissue After Switch to Doravirine

    NCT05477407 · start 2022-10-06

    Registered record
    Registry ID
    NCT05477407
    Conditions
    HIV Infections
    Interventions
    Switch from an INSTI-based regimen to the non INSTI-based regimen combining TDF/3TC/Doravirine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2022-10-06
    Completion
    2025-01-01
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionSwitch from an INSTI-based regimen to the non INSTI-based regimen combining TDF/3TC/Doravirine
    PhaseNot applicable
    Registry statusCompleted

  • The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine

    NCT05536466 · start 2022-09-30

    Registered record
    Registry ID
    NCT05536466
    Conditions
    HIV Infections; Bariatric Surgery Candidate
    Interventions
    bariatric surgery
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2022-09-30
    Completion
    2023-08-01
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Bariatric Surgery Candidate
    Interventionbariatric surgery
    PhaseNot applicable
    Registry statusUnknown